115 related articles for article (PubMed ID: 23085832)
21. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.
Granados E; de La Cámara R; Madero L; Díaz MA; Martín-Regueira P; Steegmann JL; Arranz R; Figuera A; Fernández-Rañada JM
Haematologica; 2000 Oct; 85(10):1060-7. PubMed ID: 11025598
[TBL] [Abstract][Full Text] [Related]
22. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
[TBL] [Abstract][Full Text] [Related]
23. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.
Michallet M; Sobh M; Milpied N; Bay JO; Fürst S; Harousseau JL; Mohty M; Nicolini FE; Labussière H; Tedone N; Morisset S; Vigouroux S; Baumgart J; Tabrizi R; Blaise D
Ann Hematol; 2012 Aug; 91(8):1289-97. PubMed ID: 22362122
[TBL] [Abstract][Full Text] [Related]
24. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
[TBL] [Abstract][Full Text] [Related]
25. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
[TBL] [Abstract][Full Text] [Related]
26. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor.
Mahadeo KM; Weinberg KI; Abdel-Azim H; Miklos DB; Killen R; Kohn D; Crooks GM; Shah AJ; Kharbanda S; Agarwal R; Kapoor N
Biol Blood Marrow Transplant; 2015 Mar; 21(3):440-4. PubMed ID: 25459642
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
28. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
29. Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years.
Kulkarni S; Powles R; Treleaven J; Singhal S; Horton C; Sirohi B; Bhagawati N; Tait D; Saso R; Killick S; Pinkerton R; Atra A; Meller S; Mehta J
Bone Marrow Transplant; 2000 Feb; 25(4):365-70. PubMed ID: 10723578
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
[TBL] [Abstract][Full Text] [Related]
31. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.
Slatter MA; Boztug H; Pötschger U; Sykora KW; Lankester A; Yaniv I; Sedlacek P; Glogova E; Veys P; Gennery AR; Peters C;
Bone Marrow Transplant; 2015 Dec; 50(12):1536-41. PubMed ID: 26259076
[TBL] [Abstract][Full Text] [Related]
32. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
[TBL] [Abstract][Full Text] [Related]
37. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Heli U; Eeva J; Anne N; Tapani R; Liisa V
Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
[No Abstract] [Full Text] [Related]
38. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
